Opendata, web and dolomites

BraINstorm SIGNED

Engineered nanocarriers for simultaneous anticancer immune response and “switching” of tumor-associated macrophages for intranasal glioblastoma treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BraINstorm project word cloud

Explore the words cloud of the BraINstorm project. It provides you a very rough idea of what is the project "BraINstorm" about.

model    blood    immunomodulatory    crossing    cancer    strategy    nose    administration    explored    radiotherapy    microenvironment    resection    re    combination    position    tam    lasting    regards    acid    followed    macrophages    care    appealing    immunotherapy    oligonucleotide    invasive    chemical    gbm    hyaluronic    biocompatibility    immunoconjugates    infiltrated    glioblastoma    precludes    comprise    memory    peptides    storm    reduces    types    expansion    advantage    tackle    effect    anti    macrophage    ex    education    prophylactic    oligonucleotides    tumor    performed    size    parallel    vivo    standard    clinically    treat    intrinsic    therapeutic    promotes    physical    intranasal    curable    engineer    turning    mucosa       complexity    anticancer    rate    preliminary    antigen    adhesivity    drug    nasal    conjugates    invasiveness    taas    disease    explore    brainstorm    treatment    muco    stimulation    generating    vitro    chemotherapy    assessing    barrier    50    immunotherapeutic    conventional    switch    cells    surgery    tumoral    brain    release    emerged    m2    patient    therapies    local    m1    immune    survival    route    cpg   

Project "BraINstorm" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE CATHOLIQUE DE LOUVAIN 

Organization address
address: PLACE DE L UNIVERSITE 1
city: LOUVAIN LA NEUVE
postcode: 1348
website: www.uclouvain.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 166˙320 €
 EC max contribution 166˙320 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) coordinator 166˙320.00

Map

 Project objective

Glioblastoma (GBM) remains a non-curable disease due to its high complexity and its position beyond the blood-brain barrier, which precludes access by conventional therapies. The current standard of care includes tumor resection surgery followed by radiotherapy or chemotherapy; an invasive process with a survival rate after five years is less than 5%. Tumor-associated macrophages (TAM) type 2 (M2 macrophages) comprise 30-50% of the infiltrated cells in GBM microenvironment and support tumor expansion. Immunotherapy represents an appealing strategy to treat several cancer types by turning the immune system against tumor cells; tumor antigen peptides (TAAs) recently emerged as an immunotherapeutic approach that can provide for a long-lasting immune response. Immunomodulatory oligonucleotides can “switch” M2 macrophages into M1 macrophages that produce an anti-tumoral effect. The BraINstorm (Brain INtranasal storm) project aims to engineer a hyaluronic acid (HA)-based combination conjugates that tackle GBM by the stimulation of the immune system via the delivery of TAAs and an immunomodulatory oligonucleotide (CpG) that promotes M2 macrophage “re-education” generating an “anticancer storm”. In parallel, taking advantage of the intrinsic muco-adhesivity of HA, BraINstorm will explore the nose-to-brain drug delivery, a more patient-friendly route that reduces the invasiveness. Novel combination immunoconjugates will be fully chemical-physical characterized and preliminary in vitro studies will be performed assessing the biocompatibility, drug release, and nasal mucosa barrier crossing in an ex-vivo model. Finally, the prophylactic and therapeutic activity of the HA-based conjugates will be in vivo explored in a clinically relevant GBM in vivo model through intranasal (IN) and local treatment administration with regards to effects on tumor size, immune memory, and survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINSTORM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINSTORM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

DNANanoProbes (2019)

Design of light-harvesting DNA-nanoprobes with ratiometric signal amplification for fluorescence imaging of live cells.

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

PmNC (2019)

Policy-making of early nature conservation. The Netherlands and the United Kingdom compared, 1930-1960

Read More